Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivozanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 12/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivozanib SCHEMBL29354238 | 1.00 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL172883 | 1.00 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL1869882 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL30993908 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL21174286 | 0.98 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29394095 | 0.98 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5214691 | 0.97 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5209537 | 0.97 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5211590 | 0.95 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5545131 | 0.95 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4654968-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | Alivus Life Sciences Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250339421-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622961-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | Synthon B.V. (NL) | 2025-10-01 | — | — | EP | disclosed |
| US-20250297008-A1 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | AVEO PHARMACEUTICALS INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220184079-A1 | FORMULATIONS OF A COMPOUND MODULATING KINASES | PLEXXIKON INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11344620-B2 | Combination therapies | NOVARTIS AG (CH) | 2022-05-31 | — | — | US | disclosed |
| US-20220153737-A1 | SOLID FORMS OF A COMPOUND MODULATING KINASES | DAIICHI SANKYO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-20220081436-A1 | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES | Opna Bio SA (CH) | 2022-03-17 | — | — | US | disclosed |
| WO-2022047046-A1 | METHODS OF DETECTING TRBC1 OR TRBC2 | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022046920-A2 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | KDR 1552/4885FLT1 1127/4885FLT4 593/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885FLT1 984/4885FLT4 560/4885 |
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | PBK, PDCD1LG2, CD274 | KDR 119/4885FLT1 678/4885FLT4 258/4885 |
| US-20220184079-A1 | FORMULATIONS OF A COMPOUND MODULATING KINASES | PLK1, MAP3K20, MAP3K1 | KDR 1168/4885FLT1 1497/4885FLT4 1988/4885 |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | KDR 1300/4885FLT1 1255/4885FLT4 320/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885FLT1 984/4885FLT4 560/4885 |
| US-20250339421-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | SLK, XPO7, XPO5 | KDR 3297/4885FLT1 3406/4885FLT4 2316/4885 |
| US-11344620-B2 | Combination therapies | MET, BRAF, ERBB2 | KDR 155/4885FLT1 124/4885FLT4 109/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885FLT1 984/4885FLT4 560/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | KDR 1102/4885FLT1 923/4885FLT4 821/4885 |
| US-20220081436-A1 | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES | MAP4K2, MAP4K1, MAP3K6 | KDR 814/4885FLT1 1577/4885FLT4 1345/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1552/4885FLT1 1127/4885FLT4 593/4885 |
| US-20220153737-A1 | SOLID FORMS OF A COMPOUND MODULATING KINASES | FLT3, KIT, ABL1 | KDR 210/4885FLT1 108/4885FLT4 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.